ICH M9 - reverse engineering? [Regulatives / Guidelines]

posted by dshah – India, 2020-09-17 06:46 (2 d 10:53 ago) – Posting: # 21923
Views: 88

Dear Marta,

» Do you have experience with biowaivers and ICH M9 guideline?

Many do have experience.

» When the M9 guidance mentions that we should have a formulation "qualitatively the same and quantitatively similar", especially for BCS class III drugs, how should be the quantitative formulation of the RLD justified? Is literature data enough, or do we need reverse engineering - and in this case, what is the level required (Q2 or Q3)? Only one method for each attribute or orthogonal analysis required?

When we are taking about biowaiver- mainly its for IR solid orals. and thus Q3 doesn't apply like for creams/gels/complex generic products.
Yes, indirectly reverse engineering is required and then CC/meeting with regulatory agency to confirm the similarity for Q1/Q2 could be one of the way.
Regards,
DShah

Complete thread:

Activity
 Admin contact
21,068 posts in 4,392 threads, 1,465 registered users;
online 26 (0 registered, 26 guests [including 11 identified bots]).
Forum time: Saturday 17:39 CEST (Europe/Vienna)

The purpose of models is not to fit the data,
but to sharpen the questions.    Samuel Karlin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5